metharbital

Trade name: gemonil

Small moleculeapproved

Methbarbital is a barbiturate anticonvulsant, discovered by Merck in 1905. It was introduced to market for treatment of epolepsy by Abbott in 1952, and discontinued in 1990. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1950s

  1. Jun 1, 1952

    Abbott — First NDA Organization

  2. Jun 1, 1952

    Abbott — NDA Organization

Indications

Approved for

Mechanism of action

Approval history

  • approved

Chemistry & pharmacology

Loading structure…

SMILES

CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl
Mol. weight
408.88 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-diethyl-1-methyl-
  • endiemal
  • endiemal
  • endiemal
  • gemonil
  • gemonil
  • gemonil
  • metabarbital
  • metarbital
  • metarbital
  • methabarbitone
  • metharbital
  • metharbital
  • metharbital
  • metharbital
  • metharbital
  • metharbital
  • metharbital
  • metharbital
  • metharbital
  • metharbital
  • metharbitalum
  • metharbitalum
  • metharbitone
  • metharbitone
  • methobarbitone
  • methylbarbital
  • n-methylbarbital

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
AbbVieFor profitNDA2
AbbottFor profitNDAJun 1, 1952